MCID: ADN018
MIFTS: 65

Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 77 56 15 74
Acinar Cell Adenoma 12 74
Adenomas 12 15
Acinic Cell Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 45 D000236
NCIt 51 C2855 C4196
SNOMED-CT 69 32048006 79041005

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pituitary adenoma, prolactin-secreting and villous adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Signaling by GPCR and Gastric cancer. The drugs Scopolamine and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1006)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma, prolactin-secreting 34.4 AIP GNAS MEN1
2 villous adenoma 34.3 BRAF GNAS KRAS
3 pleomorphic adenoma 34.2 PLAG1 PLAGL1 PLAGL2
4 parathyroid adenoma 34.1 CCND1 CDC73 MEN1 RET
5 sebaceous adenoma 34.0 MLH1 MSH2
6 colorectal adenoma 34.0 APC CTNNB1 KRAS MLH1 MSH2
7 periampullary adenoma 33.7 APC KRAS
8 silent pituitary adenoma 33.7 AIP MEN1
9 null pituitary adenoma 33.5 AIP MEN1
10 polyposis syndrome, hereditary mixed, 1 33.1 APC MLH1
11 hyperparathyroidism 1 33.0 CDC73 MEN1
12 acromegaly 32.7 AIP GNAS MEN1
13 mutyh-associated polyposis 32.6 APC KRAS SMAD4
14 hyperparathyroidism 2 with jaw tumors 32.6 CCND1 CDC73 MEN1 RET
15 endometrial adenocarcinoma 32.5 CTNNB1 KRAS MLH1
16 multiple endocrine neoplasia, type i 32.5 CDC73 GNAS MEN1 RET
17 parathyroid carcinoma 32.5 CCND1 CDC73 MEN1 RET
18 mismatch repair cancer syndrome 32.3 APC CTNNB1 MLH1 MSH2
19 familial adenomatous polyposis 1 32.3 APC CTNNB1
20 multiple endocrine neoplasia, type iia 32.3 CDC73 MEN1 RET
21 colorectal cancer 32.2 APC BRAF CCND1 CTNNB1 GNAS KRAS
22 familial adenomatous polyposis 32.1 APC CCND1 CTNNB1 KRAS MLH1 MSH2
23 hyperparathyroidism 31.6 CDC73 MEN1 RET
24 primary hyperparathyroidism 31.3 CCND1 CDC73 MEN1 RET
25 pituitary tumors 30.9 AIP GNAS MEN1
26 papillary carcinoma 30.8 BRAF RET TSHR
27 adenocarcinoma 30.8 APC BRAF CCND1 CTNNB1 GNAS KRAS
28 peutz-jeghers syndrome 30.8 APC CTNNB1 SMAD4
29 carney complex variant 30.7 AIP GNAS MEN1
30 thyroid cancer 30.7 APC BRAF CCND1 CTNNB1 GNAS KRAS
31 renal cell carcinoma, papillary, 1 30.4 BRAF CDC73 MSH2
32 lynch syndrome 30.4 APC BRAF CCND1 CTNNB1 KRAS MLH1
33 thyroid cancer, nonmedullary, 2 30.4 BRAF MEN1 RET TSHR
34 colon adenocarcinoma 30.3 APC CTNNB1 KRAS MLH1
35 familial colorectal cancer 30.3 APC MLH1 MSH2
36 hyperplastic polyposis syndrome 30.3 APC BRAF KRAS
37 cholangiocarcinoma 30.3 BRAF CCND1 CTNNB1 KRAS SMAD4
38 struma ovarii 30.2 BRAF RET TSHR
39 gastrointestinal stromal tumor 30.2 BRAF CCND1 KRAS MEN1
40 gastric cancer 30.2 APC CCND1 CTNNB1 KRAS MLH1 MSH2
41 thyroid carcinoma, familial medullary 30.2 KRAS MEN1 RET
42 colorectal adenocarcinoma 30.1 BRAF CTNNB1 KRAS MLH1 MSH2
43 familial isolated hyperparathyroidism 30.1 CDC73 MEN1 RET
44 intestinal disease 30.0 CCND1 CTNNB1 KRAS MLH1 MSH2
45 von hippel-lindau syndrome 29.9 CCND1 MEN1 RET
46 differentiated thyroid carcinoma 29.9 BRAF KRAS RET TSHR
47 hepatoblastoma 29.9 APC CTNNB1 PLAG1
48 ovarian cancer 29.8 BRAF CCND1 CTNNB1 KRAS MLH1 MSH2
49 bladder urothelial carcinoma 29.8 BRAF CCND1 CTNNB1 KRAS MLH1
50 suppression of tumorigenicity 12 29.8 BRAF CTNNB1 SMAD4

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

27 (show top 50) (show all 74)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 11.09 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 11.09 CTNNB1 SMAD4 KRAS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 11.09 PLAGL2 BRAF
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 11.09 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 11.09 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 11.09 KRAS
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 11.09 MEN1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 11.09 MLH1 PLAG1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 11.09 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-127 11.09 PLAGL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-128 11.09 MEN1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 11.09 MLH1 RET
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 11.09 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-133 11.09 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 11.09 MLH1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 11.09 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 11.09 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 11.09 PLAG1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 11.09 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 11.09 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-163 11.09 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-164 11.09 RET
23 Increased shRNA abundance (Z-score > 2) GR00366-A-166 11.09 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 11.09 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-176 11.09 RET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 11.09 APC CTNNB1 CCND1 KRAS MEN1 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-192 11.09 APC
28 Increased shRNA abundance (Z-score > 2) GR00366-A-194 11.09 BRAF
29 Increased shRNA abundance (Z-score > 2) GR00366-A-195 11.09 MLH1 SMAD4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-196 11.09 KRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-197 11.09 CTNNB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 11.09 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-202 11.09 APC
34 Increased shRNA abundance (Z-score > 2) GR00366-A-207 11.09 PLAG1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-21 11.09 SMAD4 CCND1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-210 11.09 CCND1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-22 11.09 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-23 11.09 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-25 11.09 SMAD4 CCND1 PLAGL2 RET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-29 11.09 APC BRAF
41 Increased shRNA abundance (Z-score > 2) GR00366-A-31 11.09 BRAF
42 Increased shRNA abundance (Z-score > 2) GR00366-A-32 11.09 BRAF
43 Increased shRNA abundance (Z-score > 2) GR00366-A-36 11.09 CCND1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-42 11.09 SMAD4
45 Increased shRNA abundance (Z-score > 2) GR00366-A-43 11.09 SMAD4 MEN1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-46 11.09 SMAD4
47 Increased shRNA abundance (Z-score > 2) GR00366-A-47 11.09 CTNNB1 MEN1 BRAF
48 Increased shRNA abundance (Z-score > 2) GR00366-A-49 11.09 APC CTNNB1 KRAS MEN1 PLAG1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-50 11.09 KRAS
50 Increased shRNA abundance (Z-score > 2) GR00366-A-52 11.09 RET

MGI Mouse Phenotypes related to Adenoma:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.54 AIP APC BRAF CCND1 CDC73 CTNNB1
2 growth/size/body region MP:0005378 10.51 AIP APC BRAF CCND1 CDC73 CTNNB1
3 endocrine/exocrine gland MP:0005379 10.49 AIP APC BRAF CCND1 CDC73 CTNNB1
4 homeostasis/metabolism MP:0005376 10.48 AIP APC BRAF CCND1 CDC73 CTNNB1
5 digestive/alimentary MP:0005381 10.44 APC BRAF CCND1 CDC73 CTNNB1 KRAS
6 cardiovascular system MP:0005385 10.43 AIP APC BRAF CCND1 CDC73 CTNNB1
7 mortality/aging MP:0010768 10.41 AIP APC BRAF CCND1 CDC73 CTNNB1
8 immune system MP:0005387 10.38 APC BRAF CCND1 CDC73 CTNNB1 GNAS
9 hematopoietic system MP:0005397 10.37 APC BRAF CCND1 CDC73 CTNNB1 GNAS
10 behavior/neurological MP:0005386 10.36 APC BRAF CCND1 CDC73 CTNNB1 GNAS
11 embryo MP:0005380 10.33 AIP APC BRAF CDC73 CTNNB1 KRAS
12 integument MP:0010771 10.3 AIP APC BRAF CCND1 CDC73 CTNNB1
13 neoplasm MP:0002006 10.28 AIP APC BRAF CCND1 CDC73 CTNNB1
14 craniofacial MP:0005382 10.26 APC BRAF CCND1 CDC73 CTNNB1 GNAS
15 nervous system MP:0003631 10.25 APC BRAF CCND1 CDC73 CTNNB1 GNAS
16 liver/biliary system MP:0005370 10.19 AIP APC BRAF CDC73 CTNNB1 GNAS
17 limbs/digits/tail MP:0005371 10.16 APC BRAF CTNNB1 GNAS KRAS PLAGL1
18 muscle MP:0005369 10.11 APC BRAF CDC73 CTNNB1 GNAS KRAS
19 reproductive system MP:0005389 10.07 APC BRAF CCND1 CDC73 CTNNB1 KRAS
20 hearing/vestibular/ear MP:0005377 10.04 APC BRAF CTNNB1 GNAS KRAS TSHR
21 normal MP:0002873 9.97 APC BRAF CCND1 CTNNB1 GNAS KRAS
22 renal/urinary system MP:0005367 9.97 APC BRAF CDC73 CTNNB1 GNAS KRAS
23 respiratory system MP:0005388 9.85 BRAF CCND1 CDC73 CTNNB1 GNAS KRAS
24 skeleton MP:0005390 9.65 APC BRAF CCND1 CDC73 CTNNB1 GNAS
25 vision/eye MP:0005391 9.23 APC BRAF CCND1 CTNNB1 KRAS MLH1

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 596)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
2
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
3
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
4
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
5
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
6
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
7
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
8
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
9
Magnesium citrate Approved Phase 4,Phase 3,Phase 2 3344-18-1
10
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
11
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
12
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
16
Glucagon Approved Phase 4,Early Phase 1 16941-32-5
17
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
18
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
19
Metformin Approved Phase 4,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
20
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
22
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
23
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
25
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
26
Parathyroid hormone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9002-64-6
27
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
28
Pasireotide Approved Phase 4,Phase 2,Phase 3,Phase 1 396091-73-9 9941444
29
Sodium sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7757-82-6
30
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
31
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051
32
Liraglutide Approved Phase 4 204656-20-2 44147092
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1 93-14-1 3516
34
Simethicone Approved Phase 4,Phase 3,Not Applicable 8050-81-5
35
Methylene blue Approved, Investigational Phase 4,Phase 3 61-73-4
36
lanreotide Approved Phase 4,Phase 3,Phase 2 108736-35-2
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Cefdinir Approved Phase 4 91832-40-5 6915944
39
Sulfamethoxazole Approved Phase 4 723-46-6 5329
40
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
41
Cefazolin Approved Phase 4 25953-19-9 656510 33255
42
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
43
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
44
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
45
Codeine Approved, Illicit Phase 4 76-57-3 5284371
46
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
47
Dyclonine Approved Phase 4 586-60-7 3180
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
49
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-70-2 271
50
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 1378)
# Name Status NCT ID Phase Drugs
1 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
3 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
4 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
5 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
6 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
7 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
8 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
9 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
10 Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
11 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
12 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
13 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
14 Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy Completed NCT01124266 Phase 4
15 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
16 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
17 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy Completed NCT02507037 Phase 4 polyethylene glycol
18 Glucagon and Colonoscopy Completed NCT02078726 Phase 4 Glucagon;Placebo
19 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
20 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
21 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
22 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
23 GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Completed NCT02283684 Phase 4
24 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
25 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
26 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
27 Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid. Completed NCT02073552 Phase 4 Polyethylene glycol 4000;Macrogol 3350 plus ascorbic acid
28 Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
29 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
30 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
31 Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid Completed NCT02761213 Phase 4 Oral sulfate solution (OSS);2-L PEG/Asc
32 Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps Completed NCT01133041 Phase 4
33 Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas Recruiting NCT03436004 Phase 4
34 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
35 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
36 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
37 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
38 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
39 Dose Individualization of Pemetrexed - IMPROVE-III Recruiting NCT03655834 Phase 4 Pemetrexed
40 Dose Individualization of Pemetrexed - IMPROVE-II Recruiting NCT03655821 Phase 4 Pemetrexed
41 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp Recruiting NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
42 Effect of Simethicone on Screening Colonoscopy Active, not recruiting NCT03119168 Phase 4 Simethicone Solution
43 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Active, not recruiting NCT02032784 Phase 4 octreotide
44 Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Active, not recruiting NCT03742232 Phase 4 PEG3350;Macrogol 4000
45 A Comparison of Eleview Versus Hetastarch as Injectate for EMR Active, not recruiting NCT03350217 Phase 4 Eleview;Hetastarch
46 Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Not yet recruiting NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
47 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Not yet recruiting NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
48 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Not yet recruiting NCT02832869 Phase 4
49 A Randomized Controlled Trial of Tailored Bowel Preparation Based on A Predictive Model Not yet recruiting NCT03704571 Phase 4 Polyethylene Glycol
50 Clinical Study on Prevention Colorectal Adenomatous Polyp Recurrence After Polypectomy Under Colonoscopy by Xiaoai Jiedu Decoction Not yet recruiting NCT03616444 Phase 4 Xiaoai Jiedu Decoction

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

42
Pituitary, Colon, Thyroid, Salivary Gland, Lung, Prostate, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 10764)
# Title Authors Year
1
A case of acromegaly caused by Rathke's cleft cyst mimicking a plurihormonal pituitary adenoma. ( 30862574 )
2019
2
Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules. ( 30742299 )
2019
3
A case of non-ampullary duodenal adenoma showing whitish color changes during potassium-competitive acid blocker treatment. ( 30689242 )
2019
4
Endoscopic Features of Sessile Serrated Adenoma/Polyps under Narrow Band Imaging: A Retrospective study. ( 30693669 )
2019
5
Adenoma and advanced neoplasia detection rates increase from 45 years of age. ( 30700941 )
2019
6
Villous Adenoma Arising in the Native Bladder Mucosa and the Upper Urinary Tract With Coexisting Neuroendocrine Carcinoma Following Augmentation Cystoplasty. ( 30701999 )
2019
7
Parathyroid adenoma presenting with spontaneous cervical and anterior mediastinal hemorrhage: A case report. ( 30702621 )
2019
8
Diagnostic pitfalls in a cystic ectopic intrathyroidal parathyroid adenoma mimicking a nodular goiter: A care-compliant case report. ( 30702624 )
2019
9
Ectopic pleomorphic adenoma on subcutaneous plane of the cheek. ( 30703863 )
2019
10
Intraductal pseudopodia in pleomorphic adenoma of parotid gland. ( 30706873 )
2019
11
Incidental retroperitoneal oncocytoma (Ectopic oncocytic adrenocortical adenoma): Case report and review of the literature. ( 30706878 )
2019
12
A Case of Primary Aldosteronism Due to A Primary Adrenal Adenoma Diagnosed by Segmental Adrenal Venous Sampling (S-AVS) Using a Modified Catheter System and Lateral Cine Angiography. ( 30710071 )
2019
13
miR-16 regulates proliferation and apoptosis of pituitary adenoma cells by inhibiting HMGA2. ( 30719118 )
2019
14
Analysis of pituitary adenoma expression patterns suggests a potential role for the NeuroD1 transcription factor in neuroendocrine tumor-targeting therapies. ( 30719226 )
2019
15
ENDOCRINE OUTCOMES OF TRANS-SPHENOIDAL SURGERY FOR PITUITARY APOPLEXY VERSUS ELECTIVE SURGERY FOR PITUITARY ADENOMA. ( 30720340 )
2019
16
PRE-OPERATIVE LOCALIZATION OF PARATHYROID ADENOMA: PERFORMANCE OF 4D MRI PARATHYROID PROTOCOL. ( 30720353 )
2019
17
Delayed postoperative hyponatremia after endoscopic transsphenoidal surgery for pituitary adenoma. ( 30721370 )
2019
18
Disagreement between high confidence endoscopic adenoma prediction and histopathological diagnosis in colonic lesions ≤ 3 mm in size. ( 30722072 )
2019
19
Parathyroid adenoma with prominent lymphocytic infiltrate having histological features highly suggestive of IgG4-related disease: a case report and literature review. ( 30726786 )
2019
20
Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. ( 30727943 )
2019
21
Pre-operative MRI predictors of hormonal remission status post pituitary adenoma resection. ( 30731423 )
2019
22
Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. ( 30732129 )
2019
23
Molecular Network Basis of Invasive Pituitary Adenoma: A Review. ( 30733705 )
2019
24
Resection of an Ectopic Parathyroid Adenoma via Video-Assisted Mediastinoscopy. ( 30735709 )
2019
25
Transcervical excision of a giant mediastinal parathyroid adenoma. ( 30737330 )
2019
26
Exacerbation of Cushing's syndrome during pregnancy: stimulation of a cortisol-secreting adrenocortical adenoma by ACTH originating from the foeto-placental unit. ( 30738017 )
2019
27
Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. ( 30738046 )
2019
28
Molecular characterization of "sessile serrated" adenoma to carcinoma transition in six early colorectal cancers. ( 30738693 )
2019
29
Evaluation of the combined effect of factors influencing bowel preparation and adenoma detection rates in patients undergoing colonoscopy. ( 30740233 )
2019
30
A novel thin wire snare-assisted en bloc cold snare endoscopic mucosal resection of a colonic adenoma 10-14 mm in size. ( 30740773 )
2019
31
Hormone replacement therapies, oral contraceptives, reproductive factors and colorectal adenomas risk: a systematic review and dose-response meta-analysis of observational studies. ( 30748083 )
2019
32
Circulating inflammation markers and colorectal adenoma risk. ( 30753331 )
2019
33
Ectopic Parathyroid Adenoma: Surgical Correction and its Complication Management. ( 30755577 )
2019
34
Extracapsular invasion: A potential prognostic marker for Carcinoma ex-pleomorphic adenoma of the salivary glands? A Systematic Review. ( 30756461 )
2019
35
Collagenous crystalloids in pleomorphic adenoma of the parotid gland. ( 30756515 )
2019
36
Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence. ( 30759066 )
2019
37
Outcomes of three-Tesla magnetic resonance imaging for the identification of pituitary adenoma in patients with Cushing's disease. ( 30760659 )
2019
38
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder. ( 30760936 )
2019
39
Colonic adenoma-associated Escherichia coli express specific phenotypes. ( 30763764 )
2019
40
Depressed-type adenoma in the colon is associated with advanced pathology. ( 30768938 )
2019
41
The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: a retrospective cohort study. ( 30773766 )
2019
42
Giant adrenal adenoma with hemorrhagic cystic degeneration. ( 30777257 )
2019
43
Hepatic adenoma during pregnancy and anesthetic management. ( 30777367 )
2019
44
Non-neoplastic signet- ring cells in a colonic tubular adenoma. ( 30782486 )
2019
45
Functional imaging of concomitant lingual thyroid and parathyroid adenoma. ( 30788533 )
2019
46
Successful Treatment of Nipple Adenoma Using Mohs Micrographic Surgery to Preserve the Nipple-Areolar Complex. ( 30789507 )
2019
47
The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. ( 30791768 )
2019
48
To cap/cuff or ring: do distal attachment devices improve the adenoma detection? ( 30791785 )
2019
49
Metagenomic analyses of the gut microbiota associated with colorectal adenoma. ( 30794590 )
2019
50
Ectopic thyroid-stimulating hormone-secreting pituitary adenoma of the nasopharynx diagnosed by 68Ga-DOTA-TATE PET/CT. ( 30797906 )
2019